PCGEM1, a Prostate-specific Gene, is Overexpressed in Prostate Cancer

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2000 Oct 26

PMID 11050243

Citations 148

Authors

V Srikantan

Z Zou

G Petrovics

L Xu

M Augustus

L Davis

J R Livezey

T Connell

I A Sesterhenn

K Yoshino

G S Buzard

F K Mostofi

D G McLeod

J W Moul

S Srivastava

Affiliations

Soon will be listed here.

Abstract

A prostate-specific gene, PCGEM1, was identified by differential display analysis of paired normal and prostate cancer tissues. Multiple tissue Northern blot analysis revealed that PCGEM1 was expressed exclusively in human prostate tissue. Analysis of PCGEM1 expression in matched normal and primary tumor specimens revealed tumor-associated overexpression in 84% of patients with prostate cancer by in situ hybridization assay and in 56% of patients by reverse transcription-PCR assay. Among various prostate cancer cell lines analyzed, PCGEM1 expression was detected only in the androgen receptor-positive cell line LNCaP. Extensive DNA sequence analysis of the PCGEM1 cDNA and genomic DNA revealed that PCGEM1 lacks protein-coding capacity and suggests that it may belong to an emerging class of noncoding RNAs, also called "riboregulators." The PCGEM1 locus was mapped to chromosome 2q32. Taken together, the remarkable prostate-tissue specificity and androgen-dependent expression of PCGEM1 as well as its elevated expression in a significant percentage of tumor tissues suggest specific functions of PCGEM1 in the biology and tumorigenesis of the prostate gland.

Citing Articles

LncRNA PCGEM1 facilitates cervical cancer progression via miR-642a-5p/KIF5B axis.

Liu Y, Liu Y, Wang Y, Wang Q, Yan Y, Zhang D Oncol Res. 2024; 32(7):1221-1229.

PMID: 38948025 PMC: 11209744. DOI: 10.32604/or.2024.047454.

Wang S, Qi X, Liu D, Xie D, Jiang B, Wang J Comput Struct Biotechnol J. 2024; 23:491-505.

PMID: 38249783 PMC: 10796827. DOI: 10.1016/j.csbj.2023.12.016.

Clinical Biofluid Assays for Prostate Cancer.

Borbiev T, Kohaar I, Petrovics G Cancers (Basel). 2024; 16(1).

PMID: 38201592 PMC: 10777952. DOI: 10.3390/cancers16010165.

An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer.

Martinez-Castillo M, Elsayed A, Lopez-Berestein G, Amero P, Rodriguez-Aguayo C Noncoding RNA. 2023; 9(6).

PMID: 37987366 PMC: 10660772. DOI: 10.3390/ncrna9060070.

H1Innovative approaches to combat anti-cancer drug resistance: Targeting lncRNA and autophagy.

Zhong C, Xie Z, Duan S Clin Transl Med. 2023; 13(10):e1445.

PMID: 37837401 PMC: 10576445. DOI: 10.1002/ctm2.1445.

References

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

Lin B, Ferguson C, White J, Wang S, Vessella R, True L . Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999; 59(17):4180-4. View

Gingrich J, Tucker J, Walther P, Day J, Poulton S, Webb K . Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). J Urol. 1991; 146(3):915-9. DOI: 10.1016/s0022-5347(17)37960-0. View

Liang P, Pardee A . Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 1992; 257(5072):967-71. DOI: 10.1126/science.1354393. View

Velleca M, Wallace M, Merlie J . A novel synapse-associated noncoding RNA. Mol Cell Biol. 1994; 14(11):7095-104. PMC: 359243. DOI: 10.1128/mcb.14.11.7095-7104.1994. View

Crespi M, Jurkevitch E, Poiret M, dAubenton-Carafa Y, Petrovics G, Kondorosi E . enod40, a gene expressed during nodule organogenesis, codes for a non-translatable RNA involved in plant growth. EMBO J. 1994; 13(21):5099-112. PMC: 395456. DOI: 10.1002/j.1460-2075.1994.tb06839.x. View

Gaddipati J, McLeod D, Sesterhenn I, Hussussian C, Tong Y, Seth P . Mutations of the p16 gene product are rare in prostate cancer. Prostate. 1997; 30(3):188-94. DOI: 10.1002/(sici)1097-0045(19970215)30:3<188::aid-pros7>3.0.co;2-i. View

Fair W, Israeli R, Heston W . Prostate-specific membrane antigen. Prostate. 1997; 32(2):140-8. DOI: 10.1002/(sici)1097-0045(19970701)32:2<140::aid-pros9>3.0.co;2-q. View

He W, Sciavolino P, Wing J, Augustus M, Hudson P, Meissner P . A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 1997; 43(1):69-77. DOI: 10.1006/geno.1997.4715. View

10.

Heselmeyer K, Macville M, Schrock E, Blegen H, Hellstrom A, Shah K . Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer. 1997; 19(4):233-40. View

11.

Reiter R, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E . Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998; 95(4):1735-40. PMC: 19171. DOI: 10.1073/pnas.95.4.1735. View

12.

Takeda K, Ichijo H, Fujii M, Mochida Y, Saitoh M, Nishitoh H . Identification of a novel bone morphogenetic protein-responsive gene that may function as a noncoding RNA. J Biol Chem. 1998; 273(27):17079-85. DOI: 10.1074/jbc.273.27.17079. View

13.

Garnick M, Fair W . Combating prostate cancer. Sci Am. 1998; 279(6):74-83. DOI: 10.1038/scientificamerican1298-74. View

14.

Erdmann V, Szymanski M, Hochberg A, De Groot N, Barciszewski J . Collection of mRNA-like non-coding RNAs. Nucleic Acids Res. 1998; 27(1):192-5. PMC: 148132. DOI: 10.1093/nar/27.1.192. View

15.

Murphy G, Tjoa B, Simmons S, Jarisch J, Bowes V, RAGDE H . Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate. 1999; 38(1):73-8. DOI: 10.1002/(sici)1097-0045(19990101)38:1<73::aid-pros9>3.0.co;2-v. View

16.

Askew D, Xu F . New insights into the function of noncoding RNA and its potential role in disease pathogenesis. Histol Histopathol. 1999; 14(1):235-41. DOI: 10.14670/HH-14.235. View

17.

Nelson P, Gan L, Ferguson C, Moss P, Gelinas R, Hood L . Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci U S A. 1999; 96(6):3114-9. PMC: 15904. DOI: 10.1073/pnas.96.6.3114. View

18.

de la Taille A, Olsson C, Katz A . Molecular staging of prostate cancer: dream or reality?. Oncology (Williston Park). 1999; 13(2):187-94; discussion 194-8, 204-5 pas. View

19.

Lanz R, McKenna N, Onate S, Albrecht U, Wong J, Tsai S . A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell. 1999; 97(1):17-27. DOI: 10.1016/s0092-8674(00)80711-4. View

20.

Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1999. CA Cancer J Clin. 1999; 49(1):8-31, 1. DOI: 10.3322/canjclin.49.1.8. View